Zacks Research Upgrades Armata Pharmaceuticals (NYSEAMERICAN:ARMP) to Hold

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) was upgraded by equities researchers at Zacks Research to a “hold” rating in a report issued on Monday,Zacks.com reports.

Separately, HC Wainwright raised their price objective on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Armata Pharmaceuticals Stock Up 11.3%

Shares of ARMP stock opened at $8.46 on Monday. The company has a 50 day moving average of $10.25 and a 200-day moving average of $8.20. Armata Pharmaceuticals has a 12-month low of $1.74 and a 12-month high of $16.34. The firm has a market cap of $310.57 million, a P/E ratio of -1.09 and a beta of 1.31.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($3.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($2.78). The firm had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.74 million. As a group, equities analysts expect that Armata Pharmaceuticals will post -1.88 EPS for the current year.

Institutional Trading of Armata Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in shares of Armata Pharmaceuticals during the fourth quarter valued at about $108,000. Bank of America Corp DE raised its stake in shares of Armata Pharmaceuticals by 233.2% during the first quarter. Bank of America Corp DE now owns 11,714 shares of the company’s stock valued at $120,000 after acquiring an additional 8,198 shares during the last quarter. Millennium Management LLC bought a new position in shares of Armata Pharmaceuticals during the fourth quarter valued at about $164,000. OMERS ADMINISTRATION Corp bought a new position in shares of Armata Pharmaceuticals during the fourth quarter valued at about $177,000. Finally, SeaCrest Wealth Management LLC raised its stake in shares of Armata Pharmaceuticals by 17.3% during the fourth quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock valued at $274,000 after acquiring an additional 6,034 shares during the last quarter. 3.57% of the stock is owned by institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.